The look at sulfonylurea compounds.

doi:10.7504/nk2014090207

Abstract

Abstract:

Abstract：Sulfonylurea compounds were the first oral antidiabetic agents in the world.They are important in optimal glucose control.Sulfonylureas not only have the function of stimulating insulin releasing from β-cells of pancreas，but also have some extrapancreatic effects，such as decreasing the clearance of hepatic insulin，reducing the secretion of glucagon in patients with type 2 diabetes mellitus and so on.Sulfonylurea compounds were the primary pharmacotherapy for type 2 diabetes mellitus patients，but their safety and clinical utility caused some controversy because of inducing the risks of hypoglycemia，gain of weight，causing cardiovascular disease outcomes and cancer in recent years.In this work，we reviewed the biological mechanisms of sulfonylureas，the efficacy of its oral taken in T2DM and the side effects of its usage and so on.

Key words: Sulfonylurea, extrapancreatic effects, clinical utility, side effects

摘要：

磺脲类药物是最为古老的口服降糖药物之一，多年的临床研究对于磺脲类药物的疗效和安全性积累了丰富的经验，使其成为目前临床上最常应用的口服降糖药物之一。磺脲类药物不仅能促进胰岛B细胞释放胰岛素，还能产生减少肝脏对胰岛素的清除、抑制胰高糖素的生成等作用。目前磺脲类药物在2型糖尿病的治疗中占有重要的地位，但是近年来磺脲类药物引起低血糖、增重、心血管事件风险等副反应逐渐引起学界的重视。WENZHANG 对磺脲类药物的作用机制、疗效、副反应和新近进展等方面做以综述。

关键词: 磺脲类药物, 额外的胰腺效应, 疗效, 副反应

CLC Number:

R587.1

ZHANG Li-na,GUO Li-xin.. The look at sulfonylurea compounds.[J]. Acta Metallurgica Sinica, DOI: 10.7504/nk2014090207.

张丽娜，郭立新. 磺脲类降糖药物的临床认识[J]. 中国实用内科杂志, DOI: 10.7504/nk2014090207.

References



[1］Barzilai N，Groop PH，Groop L，DeFronzo RA.A novel mechanism of glipizide sulfonylurea action：decreased metabolic clearance rate of insulin［J］.Acta Diabetol，1995，32：273-278. 

[2］Landstedt-Hallin L，Adamson U，Lins PE.Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes［J］.J Clin Endocrinol Metab，1999，84：3140-3145. 

[3］Braak EW，Appelman AM，van der Tweel I，Erkelens DW，van Haeften TW.The sulfonylurea glyburide induces impairment of glucagon and growth hormone responses during mild insulin induced hypoglycemia［J］.Diabetes Care，2002，25：107-112. 

[4］Cryer PE.Minireview：glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes［J］.Endocrinology，2012，153：1039-1040. 

[5］Rossetti L，Giaccari A，DeFronzo RA.Glucose toxicity［J］.Diabetes Care，1990，13：610-630. 

[6］Mandarino LJ，Gerich JE.Prolonged sulfonylurea administration decreases insulin resistance and increases insulin secretion in noninsulin-dependent diabetes mellitus：evidence for improved insulin action at a post receptor site in hepatic as well as extrahepatic tissues［J］.Diabetes Care，1984，7(Suppl 1)：89-99. 

[7］Muller G.Dynamics of plasma membrace microdomains and crosstalk to the insulin signalling cascade［J］.FEB S Lett，2002，531：81-87. 

[8］Scarsi M，Podvinecn M，Roth A，et al.Sulfonylureas and glinides exhibit peroxisome proliferator-actived receptor gamma activity：a combined virtual screening and biological assay approach［J］.Mol pharmacol，2007，71(2)：398-406. 

[9］Inzucchi SE，Bergenstal RM，Buse JB，et al.Management of hyperglycemia in type 2 diabetes：a patient-centered approach：position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)［J］.Diabetes Care，2012，35：1364-1379. 

[10］Kahn SE，Haffner SM，Heise MA，et al.Glycemic durability of rosiglitazone，metformin，or glyburide monotherapy［J］.N Eng Med，2006，355：2427-2443. 

[11］Nauck M，Frid A，Hermansen K，et al.Efficacy and safety comparison of liraglutide，glimepiride，and placebo，all in combination with metformin，in type 2 diabetes：the LEAD (Liraglutide Effect and Action in Diabetes)-2 study［J］.Diabetes Care，2009，32：84-90. 

[12］Nyenwe EA，Jerkins TW，Umpierrez GE，Kitabchi AE.Management of type 2 diabetes：evolving strategies for the treatment of patients with type 2 diabetes［J］.Metabolism，2011，60：1-23. 

[13］Petrides AS，Vogt C，Shulze-Berge D，et al.Pathogenesis of glucose intolerance and diabetes meitus in cirrhosis［J］.Hepatology，1994，19(3)：616-627. 

[14］Hartmann B，Czock D’Keller E Drug therapy in patients with chronic renal failure［J］.Drsch Arzteal Int，2010，107(37)：647-655. 

[15］Harrower AD，Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficience［J］.Clin Pharmacokinet，1996，31(2)：111-119. 

[16］Moretti ME，Rezuani M，Koren G.Safety of glyburide for gestational diabetes：a meta-analysis of pregnancy’outcomes［J］.Ann Parmacother，2008，42(4)：483-490. 

[17］NicholsonⅥBolen S，Witcop CT，et al.Benefits and risks of oral diabetes agents compared with insulin in women with gestational diabetes：a systematic review［J］.Obstet Gynecl，2009，113(1)：193-205. 

[18］Goto A，Arah OA，Goto M，Terauchi Y，Noda M.Severe hypoglycaemia and cardiovascular disease：systematic review and meta-analysis with bias analysis［J］.BMJ，2013，347：f4533. 

[19］Harrison LB，Adams-Huet B，Raskin P，Lingvay I.Beta-cell function preservation after 3.5 years of intensive diabetes therapy［J］.Diabetes Care，2012，35：1406-1412. 

[20］Remedi MS，Nichols CG.Chronic antidiabetic sulfonylureas in vivo：reversible effects on mouse pancreatic beta-cells［J］.PLoS Med，2008，5：e206. 

[21］Remedi MS，Kurata HT，Scott A，et al.Secondary consequences of beta cell inexcitability：identification and prevention in a murine model of K(ATP)-induced neonatal diabetes mellitus［J］.Cell Metabol，2009，9：140-151. 

[22］Khalangot M，Tronko M，Kravchenko V，et al.Glibenclamide-related excess in total and cardiovascular mortality risks：data from large Ukrainian observational cohort study［J］.Diabetes Res Clin Pract，2009，86(3)：247-253. 

[23］Schramm TK，Glislason GH，Vaag A，etal.Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes，with or without a previous myocardial infarcation：a nationwide study［J］.Eur Heart J，2012，33(10)：1183. 

[24］Singh S，Singh H，Singh PP，Murad MH，Limburg PJ.Anti-diabetic medications and the risk of colorectal cancer in patients with diabetes mellitus：a systematic review and meta-analysis［J］.Cancer Epidemiology Biomarkers Prevent，2013，22(12)：2258-2268. 

[25］Bo S，Castiglione A，Ghigo E，et al.Mortality outcomes of different sulphonylurea drugs：the results of a 14-year cohort study of type 2 diabetic patients［J］.Eur J Endocrinol，2013，169：117-126. 

[1]	. [J]. Acta Metallurgica Sinica, 2014, 34(12): 1212-1214.
[2]	. [J]. Acta Metallurgica Sinica, 2014, 34(12): 1219-1221.
[3]	YANG Wen-ying.. Clinical research and application of carbon glycosidase inhibitors. [J]. Acta Metallurgica Sinica, 2014, 34(10): 937-939.
[4]	ZHU Yan-hua，WENG Jian-ping.. The clinical experience of GLP-1 receptor agonist drugs. [J]. Acta Metallurgica Sinica, 2014, 34(10): 942-946.
[5]	CHEN Li-ming.. The clinical summary of thiazolidinediones in the treatment of T2DM. [J]. Acta Metallurgica Sinica, 2014, 34(10): 947-951.
[6]	LI Juan，TONG Nan-wei.. The clinical experience of glinides. [J]. Acta Metallurgica Sinica, 2014, 34(10): 959-961.
[7]	GU Guang-yu，ZHENG Shao-xiong.. SGLT2 inhibitors-new way for the treatment of type 2 diabetes. [J]. Acta Metallurgica Sinica, 2014, 34(10): 962-968.
[8]	. [J]. Acta Metallurgica Sinica, 2014, 34(10): 974-983.
[9]	LI Yan-lai*，MA Yan-qing，SUN Ji-chao，SUN Wan-wan，WANG Tian-ge，XU Yu，XU Min，BI Yu-fang，LU Jie-li.. Elevated resting heart rate is associated with increased risk of diabetes in middle-aged and elderly population. [J]. Acta Metallurgica Sinica, 2014, 34(9): 900-903.
[10]	TONG Yu-zhen，TONG Nan-wei.. Interpretation of Chinese society of endocrinology expert consensus on type 2 diabetes prevention in Chinese adults [J]. Acta Metallurgica Sinica, 2014, 34(7): 671-677.
[11]	LIU Yuan-bo*，ZHOU Bo-rong，ZHANG Ying，O De-jin，XIE Yi-juan，MENG Dong-dong.. Comparison of Clopidogrel resistance and Cilostazol resistance in patients with type 2 diabetes. [J]. Acta Metallurgica Sinica, 2014, 34(7): 693-697.
[12]	. [J]. Acta Metallurgica Sinica, 2014, 34(7): 714-715.
[13]	. [J]. Acta Metallurgica Sinica, 2014, 34(6): 619-621.
[14]	. [J]. Acta Metallurgica Sinica, 2014, 34(5): 516-517.
[15]	LVQing-guo，TONG Nan-wei.. Interpretation of Chinese Society of Endocrinology consensus statement on hyperglycemia management target in adult inpatients in China. [J]. Acta Metallurgica Sinica, 2013, 33(12): 939-941.